Loading...
End-UseCategory 4
U.S. imports of pharmaceutical preparations (End-Use 40100) totaled $16.2B in July 2026, traded with 104 countries.
Importers of Pharmaceutical Preparations paid $21.3M in duties in July 2026 — an effective duty rate of 8.8% on $240.1M in dutiable value, based on actual customs collections rather than the published tariff schedule. Pharmaceutical Preparations imports of $16.2B in July 2026 ran 12% above the year-to-date monthly average of $14.5B.
Last updated: July 2026 dataFDA admissibility review governs all imported pharmaceutical preparations, which must originate from facilities registered with FDA and comply with current Good Manufacturing Practice requirements before entry into US commerce. Import classification distinguishes among finished dosage forms packaged for retail sale, bulk active pharmaceutical ingredients, and veterinary medicaments — distinctions that carry real duty and regulatory consequences. Supply-chain resilience has become a heightened concern in this category, as concentration of API manufacturing in a small number of foreign countries has drawn sustained attention from both regulators and procurement professionals.
AI-written summary of the official U.S. Census Bureau trade figures on this page — verify before relying on it.
35.0K shipments/mo
End-Use codes describe different products on the import and export sides. Cross-direction exports are not shown for this slug.
FDA may issue a Notice of Action detaining a pharmaceutical shipment if the product appears to be adulterated, misbranded, or from an unregistered facility. The importer of record typically has an opportunity to submit testimony or reconditioning proposals to bring the goods into compliance. If the detention is not resolved, FDA can refuse admission and require the goods to be re-exported or destroyed. Working with a licensed customs broker and an FDA regulatory consultant before shipment is the most effective way to avoid detention.
Bulk APIs are generally classified under HTS Chapter 29 (organic chemicals) or Chapter 28 (inorganic chemicals) based on their chemical structure, while finished dosage forms — tablets, capsules, solutions, and similar preparations — are classified under Chapter 30 as medicaments. This distinction affects not only the duty rate but also the FDA import alert and admissibility framework that applies, since finished dosage forms trigger different review procedures than bulk chemical imports.
Commodity 1 of 30 in category 4
Commodity 40100 · $16.2B of $60.2B
Supplier Network
Get discovered by U.S. importers searching for HS 40100 — Pharmaceutical Preparations. Be the first supplier listed.
Imports · July 2026
origin
customs district
Census does not publish district detail for this classification system.
destination
Census does not publish state detail for this classification system.
entry
Census does not publish port detail for this classification system.
ImportsExports
Imports
$16.2BYoY · Pro
12-mo low · imports
YoY · ProThrough July 2026. Source: U.S. Census Bureau.